David A. Orlando
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David A. Orlando has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Chris Fiore
8 shared publications- Christian C. Fritz
Institute for Machine Tools and Industrial Management, School of Engineering and Design, Technical University of Munich, Garching, Germany
8 shared publications - Darren Lee Smith
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK; Hub for Biotechnology in the Built Environment, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
8 shared publications Jakob Lovén
8 shared publicationsJeremy T. Lopez
8 shared publications- Julie L. Koenig
Mass General Brigham Cancer Research Institute, Harvard Medical School, Boston, Massachusetts
8 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 & 6: GSEA of SY-1425 response from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 & 6: GSEA of SY-1425 response from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3: Median Survival By Cluster from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3: Median Survival By Cluster from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4: Enhancer, mRNA, and SY-1425 EC50 in AML cell lines from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4: Enhancer, mRNA, and SY-1425 EC50 in AML cell lines from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7: GREAT analysis from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
GREAT analysis of genes near H3K27ac peaks up-regulated by SY-1425 in RARA-high cell lines in perturbation gene sets
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7: GREAT analysis from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
GREAT analysis of genes near H3K27ac peaks up-regulated by SY-1425 in RARA-high cell lines in perturbation gene sets
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods and Figure Legends from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
Supplementary and expanded descriptions of methods and figure legends for supplementary data
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods and Figure Legends from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
Supplementary and expanded descriptions of methods and figure legends for supplementary data
- 2 September 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (8) , 2325-2328
Regression of Tricuspid Valve Regurgitation After Lung Transplant: A Single-Center Experience
- 2 September 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (8) , 2325-2328
Regression of Tricuspid Valve Regurgitation After Lung Transplant: A Single-Center Experience